NewsRelease
PatentApplication Cites Cleanascite™ for Culturing Pancreatic Islets
MONMOUTHJUNCTION, NJ,January11, 2018 -- Biotech Support Group reports on a recent patentapplication describing the simplicity and efficiency of their lipidclearance sample preparation technology for evaluating the influenceof lipids on pancreatic islet culture.
Thepatent application is:
Thepatent discloses compositions and methods for decreasing bloodglucagon levels. As disclosed, L-glutamine is a selective stimulatorof α-cell proliferation generated when glucagon signaling isinterrupted. A method for treating a subject with hyperglucagonemia,e.g., a subject with diabetes, that involves administering to thesubject a composition comprising an L-glutamine inhibitor in anamount effective to decrease blood glucagon levels, is disclosed. Inan example, pancreatic islets were isolated from male 8-14 week oldC57B16/J mice (Jackson Laboratory, ME) and cultured in various mediaconditions for 3 days. Thepatent states “Forlipid removal, serum was treated with Cleanascite reagent (BiotechSupport Group, Monmouth Junction, N.J.) prior to islet culture at a1:1 ratio according to the vendor's protocol.”.The example supports that increasedamino acids, but not lipids and other soluble factors, selectivelyincreased rapamycin-sensitive α-cell proliferation.
“Thisreference shows the versatility of Cleanascite™to efficiently remove lipids from serum tissue culture, so thatfactors that influence cell proliferation can be investigated.”states Swapan Roy, Ph.D., President and Founder of Biotech SupportGroup.
Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ forlipid adsorption, HemogloBind™ and HemoVoid™ forhemoglobin removal, and NuGel™ for functional proteomics. Fromthese innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com
Contact:
MatthewKuruc 732-274-2866